Cargando…
Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial
OBJECTIVE: To compare induction of labour at 41 weeks with expectant management until 42 weeks in low risk women. DESIGN: Open label, randomised controlled non-inferiority trial. SETTING: 123 primary care midwifery practices and 45 hospitals (secondary care) in the Netherlands, 2012-16. PARTICIPANTS...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598648/ https://www.ncbi.nlm.nih.gov/pubmed/30786997 http://dx.doi.org/10.1136/bmj.l344 |
_version_ | 1783430817457897472 |
---|---|
author | Keulen, Judit KJ Bruinsma, Aafke Kortekaas, Joep C van Dillen, Jeroen Bossuyt, Patrick MM Oudijk, Martijn A Duijnhoven, Ruben G van Kaam, Anton H Vandenbussche, Frank PHA van der Post, Joris AM Mol, Ben Willem de Miranda, Esteriek |
author_facet | Keulen, Judit KJ Bruinsma, Aafke Kortekaas, Joep C van Dillen, Jeroen Bossuyt, Patrick MM Oudijk, Martijn A Duijnhoven, Ruben G van Kaam, Anton H Vandenbussche, Frank PHA van der Post, Joris AM Mol, Ben Willem de Miranda, Esteriek |
author_sort | Keulen, Judit KJ |
collection | PubMed |
description | OBJECTIVE: To compare induction of labour at 41 weeks with expectant management until 42 weeks in low risk women. DESIGN: Open label, randomised controlled non-inferiority trial. SETTING: 123 primary care midwifery practices and 45 hospitals (secondary care) in the Netherlands, 2012-16. PARTICIPANTS: 1801 low risk women with an uncomplicated singleton pregnancy: randomised to induction (n=900) or to expectant management until 42 weeks (n=901). INTERVENTIONS: Induction at 41 weeks or expectant management until 42 weeks with induction if necessary. PRIMARY OUTCOME MEASURES: Primary outcome was a composite of perinatal mortality and neonatal morbidity (Apgar score <7 at five minutes, arterial pH <7.05, meconium aspiration syndrome, plexus brachialis injury, intracranial haemorrhage, and admission to a neonatal intensive care unit (NICU). Secondary outcomes included maternal outcomes and mode of delivery. The null hypothesis that expectant management is inferior to induction was tested with a non-inferiority margin of 2%. RESULTS: Median gestational age at delivery was 41 weeks+0 days (interquartile range 41 weeks+0 days-41 weeks+1 day) for the induction group and 41 weeks+2 days (41 weeks+0 days-41 weeks+5 days) for the expectant management group. The primary outcome was analysed for both the intention-to-treat population and the per protocol population. In the induction group, 15/900 (1.7%) women had an adverse perinatal outcome versus 28/901 (3.1%) in the expectant management group (absolute risk difference −1.4%, 95% confidence interval −2.9% to 0.0%, P=0.22 for non-inferiority). 11 (1.2%) infants in the induction group and 23 (2.6%) in the expectant management group had an Apgar score <7 at five minutes (relative risk (RR) 0.48, 95% CI 0.23 to 0.98). No infants in the induction group and three (0.3%) in the expectant management group had an Apgar score <4 at five minutes. One fetal death (0.1%) occurred in the induction group and two (0.2%) in the expectant management group. No neonatal deaths occurred. 3 (0.3%) neonates in the induction group versus 8 (0.9%) in the expectant management group were admitted to an NICU (RR 0.38, 95% CI 0.10 to 1.41). No significant difference was found in composite adverse maternal outcomes (induction n=122 (13.6%) v expectant management n=102 (11.3%)) or in caesarean section rate (both groups n=97 (10.8%)). CONCLUSIONS: This study could not show non-inferiority of expectant management compared with induction of labour in women with uncomplicated pregnancies at 41 weeks; instead a significant difference of 1.4% was found for risk of adverse perinatal outcomes in favour of induction, although the chances of a good perinatal outcome were high with both strategies and the incidence of perinatal mortality, Apgar score <4 at five minutes, and NICU admission low. TRIAL REGISTRATION: Netherlands Trial Register NTR3431. |
format | Online Article Text |
id | pubmed-6598648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65986482019-07-18 Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial Keulen, Judit KJ Bruinsma, Aafke Kortekaas, Joep C van Dillen, Jeroen Bossuyt, Patrick MM Oudijk, Martijn A Duijnhoven, Ruben G van Kaam, Anton H Vandenbussche, Frank PHA van der Post, Joris AM Mol, Ben Willem de Miranda, Esteriek BMJ Research OBJECTIVE: To compare induction of labour at 41 weeks with expectant management until 42 weeks in low risk women. DESIGN: Open label, randomised controlled non-inferiority trial. SETTING: 123 primary care midwifery practices and 45 hospitals (secondary care) in the Netherlands, 2012-16. PARTICIPANTS: 1801 low risk women with an uncomplicated singleton pregnancy: randomised to induction (n=900) or to expectant management until 42 weeks (n=901). INTERVENTIONS: Induction at 41 weeks or expectant management until 42 weeks with induction if necessary. PRIMARY OUTCOME MEASURES: Primary outcome was a composite of perinatal mortality and neonatal morbidity (Apgar score <7 at five minutes, arterial pH <7.05, meconium aspiration syndrome, plexus brachialis injury, intracranial haemorrhage, and admission to a neonatal intensive care unit (NICU). Secondary outcomes included maternal outcomes and mode of delivery. The null hypothesis that expectant management is inferior to induction was tested with a non-inferiority margin of 2%. RESULTS: Median gestational age at delivery was 41 weeks+0 days (interquartile range 41 weeks+0 days-41 weeks+1 day) for the induction group and 41 weeks+2 days (41 weeks+0 days-41 weeks+5 days) for the expectant management group. The primary outcome was analysed for both the intention-to-treat population and the per protocol population. In the induction group, 15/900 (1.7%) women had an adverse perinatal outcome versus 28/901 (3.1%) in the expectant management group (absolute risk difference −1.4%, 95% confidence interval −2.9% to 0.0%, P=0.22 for non-inferiority). 11 (1.2%) infants in the induction group and 23 (2.6%) in the expectant management group had an Apgar score <7 at five minutes (relative risk (RR) 0.48, 95% CI 0.23 to 0.98). No infants in the induction group and three (0.3%) in the expectant management group had an Apgar score <4 at five minutes. One fetal death (0.1%) occurred in the induction group and two (0.2%) in the expectant management group. No neonatal deaths occurred. 3 (0.3%) neonates in the induction group versus 8 (0.9%) in the expectant management group were admitted to an NICU (RR 0.38, 95% CI 0.10 to 1.41). No significant difference was found in composite adverse maternal outcomes (induction n=122 (13.6%) v expectant management n=102 (11.3%)) or in caesarean section rate (both groups n=97 (10.8%)). CONCLUSIONS: This study could not show non-inferiority of expectant management compared with induction of labour in women with uncomplicated pregnancies at 41 weeks; instead a significant difference of 1.4% was found for risk of adverse perinatal outcomes in favour of induction, although the chances of a good perinatal outcome were high with both strategies and the incidence of perinatal mortality, Apgar score <4 at five minutes, and NICU admission low. TRIAL REGISTRATION: Netherlands Trial Register NTR3431. BMJ Publishing Group Ltd. 2019-02-20 /pmc/articles/PMC6598648/ /pubmed/30786997 http://dx.doi.org/10.1136/bmj.l344 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Research Keulen, Judit KJ Bruinsma, Aafke Kortekaas, Joep C van Dillen, Jeroen Bossuyt, Patrick MM Oudijk, Martijn A Duijnhoven, Ruben G van Kaam, Anton H Vandenbussche, Frank PHA van der Post, Joris AM Mol, Ben Willem de Miranda, Esteriek Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial |
title | Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial |
title_full | Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial |
title_fullStr | Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial |
title_full_unstemmed | Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial |
title_short | Induction of labour at 41 weeks versus expectant management until 42 weeks (INDEX): multicentre, randomised non-inferiority trial |
title_sort | induction of labour at 41 weeks versus expectant management until 42 weeks (index): multicentre, randomised non-inferiority trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598648/ https://www.ncbi.nlm.nih.gov/pubmed/30786997 http://dx.doi.org/10.1136/bmj.l344 |
work_keys_str_mv | AT keulenjuditkj inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT bruinsmaaafke inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT kortekaasjoepc inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT vandillenjeroen inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT bossuytpatrickmm inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT oudijkmartijna inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT duijnhovenrubeng inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT vankaamantonh inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT vandenbusschefrankpha inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT vanderpostjorisam inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT molbenwillem inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial AT demirandaesteriek inductionoflabourat41weeksversusexpectantmanagementuntil42weeksindexmulticentrerandomisednoninferioritytrial |